

# David Kaminetzky

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9550786/publications.pdf>

Version: 2024-02-01

12  
papers

316  
citations

1306789

7  
h-index

1473754

9  
g-index

12  
all docs

12  
docs citations

12  
times ranked

726  
citing authors

#	ARTICLE	IF	CITATIONS
1	Chromothripsis as a pathogenic driver of multiple myeloma. <i>Seminars in Cell and Developmental Biology</i> , 2022, 123, 115-123.	2.3	22
2	Improving prognostic assignment in older adults with multiple myeloma using acquired genetic features, clonal hemopoiesis and telomere length. <i>Leukemia</i> , 2021, , .	3.3	8
3	Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study. <i>BMC Cancer</i> , 2021, 21, 993.	1.1	8
4	COVID-19 Infections and Clinical Outcomes in Patients with Multiple Myeloma in New York City: A Cohort Study from Five Academic Centers. <i>Blood Cancer Discovery</i> , 2020, 1, 234-243.	2.6	46
5	Pulmonary Embolism at CT Pulmonary Angiography in Patients with COVID-19. <i>Radiology: Cardiothoracic Imaging</i> , 2020, 2, e200308.	0.9	58
6	Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2018, 36, 859-866.	0.8	140
7	Pharmacokinetics-directed Intravenous Busulfan Combined With High-dose Melphalan and Bortezomib as a Conditioning Regimen for Patients With Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 650-657.	0.2	7
8	Selinexor and Low Dose Dexamethasone (Sd) in Patients with Lenalidomide, Pomalidomide, Bortezomib, Carfilzomib and Anti-CD38 Ab Refractory Multiple Myeloma (MM): STORM Study. <i>Blood</i> , 2016, 128, 491-491.	0.6	21
9	Abstract 4895: Hodgkin lymphoma patients demonstrate evidence of chronic activation/exhaustion in circulating T cell subsets. , 2016, , .		0
10	Hodgkin Lymphoma Patients Demonstrate Evidence of Systemic Perturbation of the Monocyte-Dendritic Cell Axis. <i>Blood</i> , 2016, 128, 2949-2949.	0.6	6
11	Circulating Memory T Cells Isolated from Hodgkin Lymphoma Patients Display Evidence of Exhaustion and Chronic Activation. <i>Blood</i> , 2014, 124, 4400-4400.	0.6	0
12	The Chemotherapy Regimen IVAC Is Highly Active for Multiply Relapsed and Refractory Hodgkin Lymphoma. <i>Blood</i> , 2012, 120, 4863-4863.	0.6	0